Baseline characteristics of the study population*
Men | Women | p Value | |||
---|---|---|---|---|---|
n | % or SD | n | % or SD | ||
* p Values represent comparisons between men and women for the variables listed. | |||||
Totals | 4975 | 81% | 1158 | 19% | |
Age (mean years) | 58 | 14 | 70 | 12 | <0.001 |
Mean and median number of encounters for gout | 2.7, 2 | 3 | 2.9, 2 | 2 | <0.001 |
Gout-associated comorbidities | |||||
Hypertension | 2833 | 57% | 939 | 81% | <0.001 |
Dyslipidaemia | 1894 | 38% | 491 | 42% | <0.01 |
Coronary heart disease | 943 | 19% | 287 | 25% | <0.001 |
Peripheral arterial disease | 202 | 4% | 77 | 7% | <0.001 |
Diabetes mellitus | 866 | 17% | 350 | 30% | <0.001 |
Nephrolithiasis | 153 | 3% | 27 | 2% | 0.18 |
Renal insufficiency | 485 | 10% | 204 | 18% | <0.001 |
Renal failure | 308 | 6% | 143 | 12% | <0.001 |
Drugs that can trigger or exacerbate gout (receipt of ⩾1 prescription) | |||||
Thiazide diuretics | 1487 | 30% | 636 | 55% | <0.001 |
All diuretics | 2003 | 40% | 897 | 77% | <0.001 |